Hypothesis

Mesenchymal stem cell (MSC) senescence drives batch‑to‑batch heterogeneity in exosome cargo, leading to inconsistent therapeutic potency in degenerative diseases. Selecting MSCs with low senescence markers will produce exosomes with a stable neuroprotective miRNA/protein profile, reducing variability and improving efficacy in progressive MS.

Rationale

Exosome manufacturing suffers from low yields and high variability, which the field attributes to undefined “active ingredient” [3][4]. Recent work shows that senescent MSCs alter their secretome, enriching exosomes with SASP‑linked miRNAs that can counteract regenerative signals [5]. Because senescence accumulates with passage number and culture stress, it is a plausible hidden variable behind inconsistent exosome preparations.

Testable Predictions

• MSCs exhibiting low p16INK4a expression and minimal SA‑β‑gal activity will yield exosomes with higher levels of neuroprotective miRNAs (e.g., miR‑17‑92 cluster, miR‑146a) and lower levels of pro‑inflammatory SASP miRNAs (e.g., miR‑21, miR‑155).
• Exosome batches derived from low‑senescence MSCs will show reduced batch‑to‑batch variance in protein miRNA arrays (<15% coefficient of variation) compared with batches from high‑senescence MSCs (>30% CV).
• In a biomarker‑stratified substudy of NCT07146087, patients receiving low‑senescence MSC exosomes will demonstrate slower EDSS progression and greater reduction in T2 lesion volume over 12 months than those receiving high‑senescence MSC exosomes.

Experimental Design

1. MSC Screening – Isolate MSCs from donor bone marrow, expand to passages 3, 5, and 7. Quantify senescence via flow cytometry for p16INK4a and SA‑β‑gal assay. Classify each batch as low (<5% positive) or high (>20% positive) senescence.
2. Exosome Production – Harvest conditioned media, isolate exosomes using standardized ultracentrifugation followed by size‑exclusion chromatography. Measure yield (µg protein/mL) and perform NTA for size distribution.
3. Cargo Profiling – Perform small‑RNA sequencing and targeted proteomics on each exosome batch. Compute a neuroprotective potency score based on predefined miRNA/protein ratios.
4. Variability Analysis – Calculate intra‑group CV for potency scores across three replicates per senescence class.
5. Clinical Correlation – Using existing samples from NCT07146087, match administered exosome batches to donor MSC senescence data (if available) or retrospectively assess MSC passage records. Compare EDSS change and MRI outcomes between low‑ and high‑senescence groups via ANOVA with post‑hoc Tukey correction.

If low‑senescence MSC exosomes show significantly higher potency scores, lower variability, and associate with better clinical outcomes, the hypothesis is supported. Conversely, no difference in cargo consistency or clinical effect would falsify the claim that MSC senescence is a key manufacturing bottleneck.

Potential Impact

Linking a readily measurable cell state to exosome quality offers a concrete GMP‑compatible release criterion. Implementing senescence screening could standardize potency, lower manufacturing costs, and accelerate translation of exosome therapies for MS and other degenerative conditions.